Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
CAR-T Meeting 2023
It was great to catch up with Hans Lee (@SarahCannonDocs) at #ASH25, to hear his highlights in #MultipleMyeloma!
🎥 👉
Dr Lee mentions several key trials presented (MAJESTEC-3, IFM2021-01, & IMMUNOPLANT) and notes the emerging theme of earlier…
Bispecific antibodies in myeloma: top trial updates from ASH 2025
In this video, Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN, discusses his highlights in multiple my...
ow.ly
Want to hear about the potential factors influencing the lack of survival benefit observed in the Phase III VERONA trial of venetoclax plus azacitidine in newly diagnosed HR-MDS?🤔
Then don't miss our interview with Jacqueline Garcia of @DanaFarber from #ASH25:
🎥…
At #ASH25, @pongasg of @SylvesterCancer shared insight into the ongoing Phase II TaZa CLL study investigating tafasitamab and zanubrutinib in newly diagnosed patients with CLL.
Click here to watch the interview:
👉 👈
#CLLsm #Leusm #Leukemia #CTSM…
TaZa CLL: tafasitamab and zanubrutinib in newly diagnosed CLL
Georgios Pongas, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the results of t...
ow.ly
Thank you to @Mohty_EBMT for stopping by at #ASH25 last week to share insight into the key advances & developments in GvHD management presented at the meeting!🩸
Watch the interview by clicking here:
👉 👈
#BMTsm #AMLsm #MDSsm #Myelofibrosis #HemOnc…
Advances in GvHD management presented at ASH 2025
In this interview, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses key advances and development...
ow.ly
#ASH25 Highlights | David Sallman of @MoffittNews discusses the efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed AML.🩸
Watch now:
👉 👈
#AMLsm #Leusm #HemOnc #CTSM…
Pivekimab sunirine in combination with venetoclax plus azacitidine in unfit, newly diagnosed AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the efficacy and safety of pivekimab sunirine in comb...
ow.ly
CAR-T Meeting 2023
It was great to catch up with Hans Lee (@SarahCannonDocs) at #ASH25, to hear his highlights in #MultipleMyeloma!
🎥 👉
Dr Lee mentions several key trials presented (MAJESTEC-3, IFM2021-01, & IMMUNOPLANT) and notes the emerging theme of earlier…
Bispecific antibodies in myeloma: top trial updates from ASH 2025
In this video, Hans Lee, MD, Sarah Cannon Research Institute, Nashville, TN, discusses his highlights in multiple my...
ow.ly
Want to hear about the potential factors influencing the lack of survival benefit observed in the Phase III VERONA trial of venetoclax plus azacitidine in newly diagnosed HR-MDS?🤔
Then don't miss our interview with Jacqueline Garcia of @DanaFarber from #ASH25:
🎥…
At #ASH25, @pongasg of @SylvesterCancer shared insight into the ongoing Phase II TaZa CLL study investigating tafasitamab and zanubrutinib in newly diagnosed patients with CLL.
Click here to watch the interview:
👉 👈
#CLLsm #Leusm #Leukemia #CTSM…
TaZa CLL: tafasitamab and zanubrutinib in newly diagnosed CLL
Georgios Pongas, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the results of t...
ow.ly
Thank you to @Mohty_EBMT for stopping by at #ASH25 last week to share insight into the key advances & developments in GvHD management presented at the meeting!🩸
Watch the interview by clicking here:
👉 👈
#BMTsm #AMLsm #MDSsm #Myelofibrosis #HemOnc…
Advances in GvHD management presented at ASH 2025
In this interview, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses key advances and development...
ow.ly
#ASH25 Highlights | David Sallman of @MoffittNews discusses the efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed AML.🩸
Watch now:
👉 👈
#AMLsm #Leusm #HemOnc #CTSM…
Pivekimab sunirine in combination with venetoclax plus azacitidine in unfit, newly diagnosed AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the efficacy and safety of pivekimab sunirine in comb...
ow.ly
